Experimental nasal spray may slow Parkinson's progression, FIU researchers say

Florida International University researchers are developing an experimental nasal spray called CTS2444-32 intended to reach deep brain regions and potentially slow Parkinson's progression; lead researcher Kim Tieu said a therapy could be possible in about five years if development goes well.

A team at Florida International University is developing an experimental nasal spray intended to slow progression of Parkinson's disease. The compound is named CTS2444-32. Researchers say the nasal delivery is designed to reach deep brain regions affected by the condition. Scientists describe the approach as aiming to modify the disease rather than only treating symptoms. Key details: - The compound under development is called CTS2444-32 and is being tested as a nasal spray delivery system. - Researchers report the formulation is designed to reach deep brain regions affected by Parkinson's disease. - The approach aims to modify the disease process rather than primarily replacing dopamine to manage symptoms. - Lead researcher Kim Tieu said the drug builds on existing drugs that have U.S. Food and Drug Administration approval, which researchers say could shorten development time. - Tieu said that if things go well, a therapy might be possible in roughly five years. - A patient quoted in the report, Jane Reiner, is participating in a clinical trial and described the goal as slowing progression rather than curing the disease. Summary: Researchers describe this work as a potential shift toward disease-modifying therapy for Parkinson's, rather than symptom management alone. Clinical testing is underway and the timeline for a widely available therapy remains uncertain, with researchers reporting an optimistic estimate of about five years if development proceeds successfully.